A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease

NCT02513459 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Risankizumab 600 mg IV
DRUG: Risankizumab 180 mg SC

Sponsor

AbbVie

Collaborators

[object Object]